Tardive dyskinesia places high physical, social, and psychological burdens on patients and their caregivers. A new online survey of U.S. caregivers spotlights their struggles. Share on Facebook.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

The company noted that the KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on tardive dyskinesia or TD using ...

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

TD, or tardive dyskinesia, is pretty much uncontrollable, jerky movements of the body. Smacking of the lips, licking, or jaw movements. I have Tourette's, and I kind of feel like it's just an ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing sales forecast for tardive dyskinesia (TD) drug Ingrezza commanded much of ...

After suffering from a long battle with Tardive Dyskinesia and Parkinsons Disease Glenn R. Buddy Clark, age 69, passed away at the South Mountain Restoration Center on Sunday, February 16 ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock ...